Faeth Therapeutics Inc.
FTH | NASDAQ
$18.69
-$0.06 (-0.32%)
At close: Oct 30, 2026, 4:00 PM ET
$18.32
-$0.37 (-1.98%)
After-hours:
Oct 30, 2026, 7:30 PM ET
-0.32%
(1D)No price chart data available for 1D timeframe.
Rating
46.5
+9.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #353/1028 (Top 34%)
Key Statistics
Market Data
Market Cap $481.8M
1D Range
17.88 19.04
52W Range
7.89 40.05
Valuation (TTM)
PE -0.13
PB 2.79
EV/EBITDA -1.51
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $58.50
Cash Flow
FCF Yield -7.0%
SBC Adj. FCF Yield -10.8%
SBC Impact -52.9%
Margins
Gross Margin 2740.8%
Operating Margin 4098.5%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
-100.0%
Dil EPS 3Y | 5Y -95.0% |
-45.3%
FCF 3Y | 5Y -17.2% |
6.4%
Returns
ROA -103.3%
ROE -192.8%
ROIC -110.3%
Financial Health
Net Cash
$186.44M
Current Ratio 19.69
Interest Coverage -22,091.11
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company'...
Sector Healthcare
Industry Biotechnology
Employees 29
IPO Date Feb 4, 2021
Website www.faeththerapeutics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$58.00
Upside
+210.33%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove FTH